RBC Capital downgraded Jasper Therapeutics (JSPR) to Sector Perform from Outperform with a price target of $5, down from $46.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- Jasper Therapeutics downgraded to Market Perform from Outperform at BMO Capital
- Hold Rating for Jasper Therapeutics Amid Uncertainties in Briquilimab’s Clinical Trials and Competitive Challenges
- Cantor cuts Jasper Therapeutics to Neutral after briquilimab update
- Jasper Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- Buy Rating Maintained for Jasper Therapeutics Amid Manufacturing Setback and Promising Drug Profile